Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Page Path

Original Article

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Yun Bin Lee1,2, Yeonjung Ha1, Young Eun Chon1, Mi Na Kim1, Joo Ho Lee1, Hana Park1, Kwang-il Kim3, Soo-Hwan Kim4,5, Kyu Sung Rim1, Seong Gyu Hwang1orcid
Clinical and Molecular Hepatology 2019;25(1):52-64.
Published online: October 23, 2018

1Division of Hepatology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea

2Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

3Department of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea

4Bio-Age, Medical Research Institute, Seoul, Korea

5Department of Statistics, LSK Global Pharma Services Co., Ltd., Seoul, Korea

Corresponding author : Seong Gyu Hwang Division of Hepatology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam 13496, Korea Tel: +82-31-780-5213, Fax: +82-31-780-5219 E-mail: sghwang@cha.ac.kr
• Received: May 15, 2018   • Revised: August 30, 2018   • Accepted: September 11, 2018

Copyright © 2019 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 13,433 Views
  • 378 Download
  • 91 Web of Science
  • 87 Crossref
  • 97 Scopus
prev next

Full Article

Download PDF Download PDF
See the commentary-article "Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on." in Volume 25 on page 40.
  • Background/Aims
    Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic steatosis on the risk for hepatocellular carcinoma (HCC) in CHB patients without excessive alcohol intake.
  • Methods
    Consecutive CHB patients who underwent liver biopsy from January 2007 to December 2015 were included. The association between hepatic steatosis (≥ 5%) and subsequent HCC risk was analyzed. Inverse probability weighting (IPW) using the propensity score was applied to adjust for differences in patient characteristics, including metabolic factors.
  • Results
    Fatty liver was histologically proven in 70 patients (21.8%) among a total of 321 patients. During the median (interquartile range) follow-up of 5.3 (2.9–8.3) years, 17 of 321 patients (5.3%) developed HCC: 8 of 70 patients (11.4%) with fatty liver and 9 of 251 patients (3.6%) without fatty liver. The five-year cumulative incidences of HCC among patients without and with fatty liver were 1.9% and 8.2%, respectively (P=0.004). Coexisting fatty liver was associated with a higher risk for HCC (adjusted hazards ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03). After balancing with IPW, HCC incidences were not significantly different between the groups (P=0.19), and the association between fatty liver and HCC was not significant (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47).
  • Conclusions
    Superimposed NAFLD was associated with a higher HCC risk in CHB patients. However, the association between steatosis per se and HCC risk was not evident after adjustment for metabolic factors.
  • Keywords: Hepatitis B virus; Fatty liver; Nonalcoholic fatty liver disease (NAFLD); Metabolic syndrome; Liver cancer
·The prevalence of histologically proven fatty liver was 21.8%, and coexisting fatty liver was associated with a 3–fold increased risk for hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients without excessive alcohol intake.
·However, when demographic and clinical characteristics including metabolic factors were balanced using inverse probability weighting based on each patient’s propensity score, the association between coexistence of fatty liver and HCC development was not evident.
·These findings suggest that superimposed nonalcoholic fatty liver disease (NAFLD) as a hepatic manifestation of metabolic syndrome, not hepatic steatosis per se, may possess important predictive value for HCC in CHB patients.
Chronic hepatitis B virus (HBV) infection is one of the most common chronic viral infections worldwide, and especially in Asian countries [1]. Patients with chronic hepatitis B (CHB) are at risk for developing liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC) [2-4]. Although the long-term prognosis for patients with chronic HBV infection has been improved by antiviral therapy with potent nucleos(t)ide analogues (i.e., entecavir, tenofovir disoproxil or tenofovir alafenamide), the risk for developing HCC has not been eliminated in those patients, leading to a huge burden on public health [5]. Patients with HBV-related cirrhosis are at a particularly high risk for HCC development, with a yearly incidence of HCC in those patients ranging from 2% to 8% [5].
Nonalcoholic fatty liver disease (NAFLD) is another serious global health problem because of the increasing prevalence even in Asian countries. Although its pathogenesis is not fully understood, NAFLD is primarily associated with obesity and insulin resistance, and is regarded as a hepatic manifestation of metabolic syndrome [6]. A diverse spectrum of liver diseases including nonalcoholic steatohepatitis (NASH) and liver cirrhosis results from NAFLD, and NAFLD is a well-known risk factor for HCC [7]. Patients with NASH-related cirrhosis are at a greatly increased risk for HCC, with a yearly cumulative incidence of 2.6% [8]. Theoretically, NAFLD and chronic HBV infection may synergistically potentiate HCC development; however, few studies have evaluated the effect of coexisting NAFLD on the risk for developing HBV-related HCC. A recent study showed that CHB patients with histologically proven fatty liver had a 7.3–fold increased risk for developing HCC [9]. While age, long-term antiviral treatment, and cirrhosis were independent predictive factors for HCC development, metabolic factors such as diabetes, hypertension, and body mass index (BMI), were not. However, a previous Taiwanese study demonstrated that both concurrent obesity and diabetes were predictors of HCC risk in patients with CHB, suggesting a synergistic hepatocarcinogenic effect of metabolic factors and chronic viral hepatitis [10].
The present study was conducted to evaluate the effect of histologically proven fatty liver on the development of HCC in patients with chronic HBV infection. We adopted inverse probability weighting (IPW) based on each patient’s propensity score to rigorously adjust for possible confounding factors, including metabolic factors.
Patient population
The study population consisted of consecutive CHB patients who underwent liver biopsy from January 2007 through December 2015 at CHA Bundang Medical Center (Seongnam, Korea). We excluded patients with significant alcohol intake (n=7), which was defined as alcohol consumption of more than 210 g per week in males and 140 g per week in females over a 2-year period preceding liver biopsy [11,12]. Patients who met any of the following criteria also were excluded from the study: (1) history of malignant disease, including HCC (n=11); (2) co-infection with hepatitis C virus (n=1); (3) a follow-up duration of less than 6 months (n=48); or (4) HCC diagnosed within 6 months from baseline (n=1) (Fig. 1). The study protocol was reviewed and approved by the Institutional Review Board of CHA Bundang Medical Center. Because this study was a retrospective cohort study based on pre-existing clinical data, which were analyzed anonymously, the need for obtaining a written informed consent was waived.
Clinical and histological assessment
All patients admitted for liver biopsy and clinical and laboratory parameters were assessed at baseline. BMI was calculated based on body weight and height at the time of admission. Overweight was defined as BMI ≥ 23 kg/m2, and obesity was defined as BMI ≥ 25 kg/m2 in accordance with BMI cut-off points for determining overweight and obesity in Asian populations [13]. The following laboratory parameters were evaluated at baseline: hepatitis B e antigen (HBeAg), HBV DNA levels, and blood chemistry parameters, including albumin, total bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase (ALT), gamma-glutamyl transferase, fasting glucose, and lipid profiles. Dyslipidemia was defined as serum triglyceride ≥ 150 mg/dL or high-density lipoprotein (HDL) cholesterol < 40 mg/dL in males and < 50 mg/dL in females [14]. The study patients were usually assessed at 3- to 6-month intervals throughout the entire follow-up period. Follow-up duration was defined as the period between the date of liver biopsy and the date of HCC diagnosis or last visit. Patients were treated with nucleos(t)ide analogues based on international guidelines and the physician’s decision. Most patients underwent regular HCC surveillance with abdominal imaging (e.g., ultrasonography or computed tomography) and/or monitoring of alpha-fetoprotein levels every 6–12 months. HCC diagnosis was established radiologically or histologically according to practice guidelines [15-18].
Ultrasound-guided liver biopsy was performed during inpatient stay. Histopathologic diagnosis was made by an experienced hepatopathologist (K.I.K.) who had no clinical information regarding the study subjects. A liver biopsy specimen was considered adequate if it was longer than 1.5 cm and contained six or more portal triads [19]. Hepatic fibrosis was assessed semiquantitatively according to the Ishak scoring system (score 0–6), and cirrhosis was defined as severe fibrosis with Ishak score 5 or 6 [20]. Fatty liver was defined as the presence of ≥ 5% hepatic steatosis [11].
Statistical analysis
We compared the baseline demographic and clinical characteristics of patients with or without fatty liver. Continuous variables were expressed as median and interquartile range, and groupwise comparisons were performed using Student’s t-test. The chi-squared test was used to compare categorical variables. The cumulative incidence rates of HCC were plotted using the Kaplan-Meier method, and differences between groups were compared using the log-rank test. The Cox proportional hazards model was used to identify risk factors for development of HCC. Clinicopathological factors were tested in a univariate analysis; and then a multivariate analysis was performed with factors that showed a significant association in the univariate analysis. Presence of fatty liver was included in the multivariate analysis, even if it was not identified as a significant risk factor in the univariate analysis, to evaluate its adjusted predictive value for HCC.
We employed IPW using the propensity score to adjust for between-group differences in patient characteristics, including metabolic factors. Propensity scores were computed by fitting a logistic regression model, in which demographic and clinicopathological characteristics were included, and the presence of fatty liver was deemed an outcome. The balance of baseline characteristics between groups was re-evaluated after IPW; and thereafter, the weighted Cox proportional hazards model was used to explore independent risk factors for HCC development. All statistical analyses were conducted as 2-tailed tests using IBM SPSS, version 24.0 (IBM Corp., Armonk, NY, USA) and R language, version 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was declared with a P-value less than 0.05.
Characteristics of the study population
A total of 321 patients with chronic HBV infection were included in the analysis. Steatosis of ≥ 5% was identified in 70 patients (21.8%), and the median (interquartile range [IQR]) follow-up duration was 5.3 (2.9–8.3) years. None of the study patients died or underwent liver transplantation during the follow-up period. Baseline demographic and clinicopathological characteristics of the study subjects are summarized in Table 1. The median (IQR) age was 41 (33–49) years overall and the patients with fatty liver were significantly older than those without fatty liver (P=0.005). BMI was higher in patients with fatty liver than that of patients without fatty liver, and 55.7% of patients with fatty liver were obese (BMI ≥ 25 kg/m2). Diabetes (P=0.06) and hypertension (P=0.005) were more prevalent among patients with fatty liver than among those without fatty liver. Patients with fatty liver had significantly more metabolic risk factors, which included obesity, history of hypertension or diabetes mellitus, and higher serum levels of triglyceride and fasting glucose, lower serum levels of HDL cholesterol, compared to patients without fatty liver (P<0.001). Serum concentrations of total cholesterol, low-density lipoprotein cholesterol, and triglyceride were higher among patients with fatty liver (P<0.001). Fasting glucose concentrations were also higher in patients with fatty liver; however, this difference between the two groups was not statistically significant (P=0.09). Cirrhosis was more frequently diagnosed in patients with fatty liver, but the difference between groups was not significant (P=0.09). Almost all patients (n=302; 94.1%) received antiviral therapy, and 167 patients (52.0%) were treated for over 5 years. The majority of study patients were HBeAg-positive, and the proportion of HBeAg-positive patients and HBV DNA levels at baseline were similar between the groups (P=0.11 and P=0.26, respectively).
Development of HCC
During the follow-up period, 17 patients (5.3%) were diagnosed with HCC: 8 (11.4%) among 70 patients with fatty liver and 9 (3.6%) among 251 patients without fatty liver. The 1-year, 3-year, and 5-year cumulative incidences of HCC were 0%, 1.8%, and 3.2%, respectively, and the rates differed significantly between the groups (P=0.004): 0%, 1.9%, and 1.9% among the patients without fatty liver and 0%, 1.6%, and 8.2% among those with fatty liver (Table 2, Fig. 2A, B). When the patients were divided into two subgroups according to the presence of cirrhosis, the 5-year cumulative incidences of HCC were 2.1% in the subgroup without cirrhosis (Ishak F0–4) and 8.0% in the subgroup with cirrhosis (Ishak F5/6) (Table 2). While the 5-year cumulative incidence rates were significantly higher among patients with fatty liver than among patients without fatty liver in the subgroup without cirrhosis (n=257: 6.0% vs. 1.1%; P=0.04) (Table 2, Fig. 2C), the 5-year cumulative incidence rates were not significantly different between the two groups within the subgroup with cirrhosis (n=64: 13.7% vs. 5.3%; P=0.11) (Table 2, Fig. 2D).
A univariate Cox proportional hazards regression analysis identified age, diabetes mellitus, hypertension, cirrhosis, baseline serum ALT levels, and fatty liver as risk factors for HCC development (Table 3). A multivariate analysis with forward stepwise variable selection revealed a significant association between coexistence of fatty liver and an increased risk for HCC development (adjusted hazard ratio [HR], 3.005; 95% confidence interval [CI], 1.122–8.051; P=0.03) (Table 3). Age (adjusted HR, 1.109; 95% CI, 1.057–1.164; P<0.001) and cirrhosis (adjusted HR, 2.939; 95% CI, 1.088–7.935; P=0.03) were determined as independent risk factors for HCC development (Table 3).
HCC risk assessment using IPW
Baseline demographic and clinicopathological characteristics, including age, gender, BMI, diabetes, hypertension, and lipid profiles, became well balanced between the groups after adjustment for patient characteristics using IPW (Table 4). The weighted cumulative incidence rate of HCC at year 5 was 2.6% overall (Fig. 3A): 2.0% among the patients without fatty liver and 5.3% among those with fatty liver (Fig. 3B). There was no statistically significant difference in the 5-year cumulative risk for developing HCC between the two groups (P=0.19) (Fig. 3B). Moreover, the cumulative HCC incidence rates were similar between the groups in the subgroups without and with cirrhosis (P=0.16 and P=0.97, respectively) (Fig. 3C, D). When the weighted Cox proportional hazard models were fitted, a subsequent univariate analysis identified age, diabetes mellitus, and cirrhosis status as factors significantly associated with development of HCC (Table 5). In the multivariate Cox model, older age (adjusted HR, 1.063; 95% CI, 1.010–1.120; P=0.02) and status of diabetes mellitus (adjusted HR, 3.562; 95% CI, 1.117–11.359; P=0.03) were significantly associated with HCC risk, whereas coexistence of fatty liver (adjusted HR, 1.709; 95% CI, 0.404–7.228; P=0.47) and cirrhosis (adjusted HR, 3.554; 95% CI, 0.911–13.874; P=0.07) showed no significant association with HCC risk (Table 5).
In the present study, we demonstrated that the prevalence of histologically proven fatty liver was 21.8%, and coexistence of fatty liver was associated with a 3–fold increased risk for developing HCC in CHB patients without excessive alcohol consumption. Age and liver cirrhosis were additional independent risk factors for HCC in our study population. However, after rigorous adjustment for patient characteristics including metabolic factors using IPW, no significant association between coexistence of fatty liver and HCC development was observed. Instead, diabetes showed significant association with risk potentiating HCC development by 3.6–fold.
Because we aimed to accurately assess the hepatocarcinogenic effect of coexisting NAFLD in Korean patients with chronic HBV infection, patients undergoing liver biopsy and subsequent histologic diagnosis, which is the gold standard for assessment of hepatic steatosis [11], were selected for analysis. After adjusting for age and cirrhosis, histologically diagnosed NAFLD was determined to be an independent predictive factor of HCC development. Although diabetes and hypertension were identified as significant risk factors for HCC in a univariate analysis, these factors were excluded in the variable selection process for multivariate analysis. Intriguingly, the impact of fatty liver on the risk for developing HCC in CHB patients disappeared under conditions in which possible confounders, including metabolic factors, were thoroughly controlled. Cirrhosis, which is a well-known risk factor of HCC, was adjusted in the multivariate analysis and IPW, however, the impact of coexisting fatty liver might be attenuated in cirrhotic patients. Therefore, we repeated weighted analyses in the subgroup of non-cirrhotic patients (n=257). As results, the cumulative risks of developing HCC were not significantly different between patients without and with fatty liver (P=0.23 by weighted log-rank test). Moreover, coexistence of fatty liver was not associated with HCC risk (adjusted HR, 4.564; P=0.07) after adjustment for age (adjusted HR, 1.099; P=0.004), diabetes (adjusted HR, 7.018; P=0.007), and ALT (adjusted HR, 0.988; P=0.05). Overall, the obtained results were similar to those in the total study population. These findings suggest that coexisting NAFLD as a hepatic manifestation of metabolic syndrome potentiates the risk for HCC in CHB patients, but hepatic steatosis per se does not.
Consistent with our present study, Chan and colleagues recently reported that histologically proven fatty liver was associated with a 7.3–fold increased risk for HCC development in patients chronically infected with HBV [9]. In another study, when the influence of metabolic risk factors, such as obesity, diabetes mellitus, hypertension, and hypertriglyceridemia, on HCC risk and liver-related mortality in male patients with chronic HBV infection was analyzed, patients with ≥ 3 metabolic risk factors were at a 2.3–fold higher risk for HCC [21]. Particularly, the association of metabolic risk factors and insulin resistance with HCC risk was more evident in patients with low viral load (HBV DNA < 10,000 copies/mL), and this point supports findings in our present study, in which more than 90% of the study subjects were treated with antiviral therapies. Although results of the previous study drawn from a large Taiwanese cohort with long-term follow-up did not include data on the effects of histologically proven fatty liver, the results were in line with findings in our present study. Collectively, thorough screening and management of metabolic risk factors in CHB patients is crucial for preventing HCC, and ultimately improving the long-term clinical outcomes. In the present study, cirrhosis, a well-known major risk factor for HCC [5], was revealed to possess a significant association with a 2.9–fold increased risk for developing HCC. Coexisting fatty liver potentiated the HCC risk in patients without cirrhosis (Ishak F0–4), whereas did not in those with cirrhosis (Ishak F5/6). These results implicate that modifiable metabolic factors need be dealt with more strictly in young non-cirrhotic patients with chronic HBV infection.
In our study population, the prevalence of histologically proven fatty liver was 21.8%. Concurrent fatty liver was histologically diagnosed in 39.6% of the CHB patients included in the aforementioned study [9], and the prevalence of histologically proven fatty liver in Chinese CHB patients was reported to have gradually increased from 8.2% to 31.8% over 10 years [22]. Although the CHB patients included in our present study showed a lower prevalence of NAFLD when compared with those study population, NAFLD is becoming more prevalent as obesity becomes a worldwide epidemic. Therefore, physicians have to become more alert to the possibility of metabolic syndrome when treating patients with chronic HBV infection in the future.
There are several limitations to this study. First, we did not adopt the scoring systems for semiquantitative severity assessment of necroinflammation in NAFLD, such as NAFLD activity score and steatosis-activity-fibrosis score [23-25]. NAFLD is generally regarded as benign, and there are few reports of HCC developing from simple hepatic steatosis. However, the influence of NASH on the risk for HCC in CHB patients is worthy of further investigation. Second, because our data were collected retrospectively, insulin resistance, which plays a key role in glucose and lipid metabolism, could not be fully assessed in the present study. Moreover, the use of statin or metformin, a possible confounding factor, was not available for adjustment in our retrospective cohort. Prospective studies are warranted that evaluate the association between coexisting fatty liver and HCC risk, with adjustment for metabolic parameters reflecting insulin resistance, such as the homeostasis model assessment of insulin resistance index, and medication history [26]. Third, liver cirrhosis, a well-known risk factor for HCC, was not independent predictor of development of HCC after IPW, this finding might result from limited events during our study period and the association between liver cirrhosis and HCC risk would become evident with accumulation of events over time.
In conclusion, we demonstrated that coexisting fatty liver was associated with an increased risk for HCC development in patients with chronic HBV infection. However, considering that the association was not evident after adjusting for metabolic factors, fatty liver as a hepatic manifestation of metabolic syndrome, may possess important predictive value for HCC. Thorough screening and management of metabolic risk factors is needed to improve the long-term outcomes of patients chronically infected with HBV.

Author contribution

The corresponding author (Seong Gyu Hwang) had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Yun Bin Lee and Seong Gyu Hwang.

Provision of study materials or patients: Yun Bin Lee, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, and Seong Gyu Hwang.

Collection and assembly of data: Yun Bin Lee, Yeonjung Ha, and Kwang-il Kim.

Data analysis and interpretation: Yun Bin Lee, Soo-Hwan Kim, and Seong Gyu Hwang.

Manuscript writing: Yun Bin Lee and Seong Gyu Hwang.

Final approval of manuscript: All authors.

Grant support

This study was supported by a grant of the Korea Healthcare Technology R&D project, funded by the Ministry for Health, Welfare & Family Affairs, Republic of Korea (HI13C1398).

Conflicts of Interest The authors declare that they have no competing interests.

Figure 1.
Flowchart of patient identification for the study. A total of 321 patients with chronic HBV infection were included in the analysis. HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HBV, hepatitis B virus.
cmh-2018-0040f1.jpg
Figure 2.
Incidence of HCC. (A) In the entire cohort. (B) Among patients with or without fatty liver. (C) Among patients with or without fatty liver in the subgroup without cirrhosis (Ishak F0–4). (D) Among patients with or without fatty liver in the subgroup with cirrhosis (Ishak F5/6). HCC, hepatocellular carcinoma.
cmh-2018-0040f2.jpg
Figure 3.
Incidence of HCC after IPW. (A) In the entire cohort. (B) Among patients with or without fatty liver. (C) Among patients with or without fatty liver in the subgroup without cirrhosis (Ishak F0–4). (D) Among patients with or without fatty liver in the subgroup with cirrhosis (Ishak F5/6). HCC, hepatocellular carcinoma; IPW, inverse probability weighting.
cmh-2018-0040f3.jpg
Table 1.
Baseline clinicopathological characteristics
Table 1.
Characteristics Overall (N=321) Steatosis
 P-value
< 5% (n=251) ≥ 5% (n=70)
Age (median [IQR]) (years) 41 (33–49) 41 (32–48) 45 (36–51) 0.005
Male 196 (61.1) 146 (58.2) 50 (71.4) 0.05
BMI (kg/m2) <0.001
 <23 (Normal) 134 (41.7) 118 (47.0) 16 (22.9)
 ≥23 to <25 (Overweight) 81 (25.2) 66 (26.3) 15 (21.4)
 ≥25 (Obese) 106 (33.0) 67 (26.7) 39 (55.7)
Diabetes mellitus 21 (6.5) 13 (5.2) 8 (11.4) 0.06
Hypertension 25 (7.8) 14 (5.6) 11 (15.7) 0.005
Number of metabolic risk factors* <0.001
 <3 269 (83.8) 223 (88.8) 46 (65.7)
 ≥3 52 (16.2) 28 (11.2) 24 (34.3)
Liver cirrhosis 64 (19.9) 45 (17.9) 19 (27.1) 0.09
Duration of antiviral treatment 0.88
 Never or <5 years 154 (48.0) 121 (48.2) 33 (47.1)
 ≥5 years 167 (52.0) 130 (51.8) 37 (52.9)
Laboratory data (median [IQR])
 Albumin (g/dL) 4.0 (3.7–4.3) 4.0 (3.7–4.3) 4.2 (3.8–4.4) 0.17
 Total bilirubin (mg/dL) 0.6 (0.5–0.9) 0.7 (0.5–0.9) 0.6 (0.5–0.9) 0.53
 ALP (IU/L) 185 (154–241) 191 (156–245) 176 (150–227) 0.17
 AST (IU/L) 76 (47–140) 85 (51–153) 53 (36–86) <0.001
 ALT (IU/L) 87 (44–160) 94 (45–171) 71 (32–114) 0.02
 GGT (IU/L) 61 (32–112) 66 (33–115) 52 (30–104) 0.51
 Fasting glucose (mg/dL) 98 (90–109) 98 (90–108) 103 (92–117) 0.09
 Total cholesterol (mg/dL) 164 (140–183) 159 (137–179) 176 (155–203) <0.001
 HDL cholesterol (mg/dL) 47.3 (38.8–58.4) 48.3 (39.4–59.4) 44.4 (35.4–54.4) 0.21
 LDL cholesterol (mg/dL) 92 (76–112) 90 (75–108) 105 (87–129) <0.001
 Triglyceride (mg/dL) 84 (65–115) 80 (63–109) 103 (81–137) <0.001
 HBeAg (positive) 218 (67.9) 176 (70.1) 42 (60.0) 0.11
 HBV DNA 0.26
  <6 log10 copies/mL 146 (45.5) 110 (43.8) 36 (51.4)
  ≥6 log10 copies/mL 175 (54.5) 141 (56.2) 34 (48.6)

Data are given as number (%) of patients, unless otherwise noted.

IQR, interquartile range; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gammaglutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

*Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

Table 2.
Development of HCC
Table 2.
HCC development Overall Steatosis < 5% Steatosis ≥ 5%
Overall
 1-year Rate (%) 0 0 0
Sample size 310 243 67
 3-year Rate (%) 1.8 1.9 1.6
Sample size 238 184 54
 5-year Rate (%) 3.2 1.9 8.2
Sample size 164 136 28
Ishak F0–4
 1-year Rate (%) 0 0 0
Sample size 248 198 50
 3-year Rate (%) 0.9 1.1 0
Sample size 191 151 40
 5-year Rate (%) 2.1 1.1 6.0
Sample size 141 120 21
Ishak F5/6
 1-year Rate (%) 0 0 0
Sample size 62 45 17
 3-year Rate (%) 5.6 5.3 5.9
Sample size 47 33 14
 5-year Rate (%) 8.0 5.3 13.7
Sample size 23 16 7

HCC, hepatocellular carcinoma.

Table 3.
Univariate and multivariate Cox analysis of the factors associated with HCC development
Table 3.
Characteristics HCC development
Univariate analysis
 Multivariate analysis
Hazard ratio (95% CI) P-value Adjusted hazard ratio (95% CI) P-value
Age (years) 1.105 (1.057–1.155) <0.001 1.109 (1.057–1.164) <0.001
Male 1.403 (0.494–3.986) 0.53
BMI (kg/m2) 0.52
 <23 (Normal) 1 [Reference]
 ≥23 to <25 (Overweight) 1.851 (0.535–6.403) 0.33
 ≥25 (Obese) 1.826 (0.579–5.761) 0.30
Diabetes mellitus 0.002
 No 1 [Reference]
 Yes 6.019 (1.893–19.139)
Hypertension 0.008
 No 1 [Reference]
 Yes 4.138 (1.452–11.791)
Number of metabolic risk factors* 0.95
 <3 1 [Reference]
 ≥3 1.045 (0.299–3.651)
Liver cirrhosis 0.007 0.03
 No 1 [Reference] 1 [Reference]
 Yes 3.880 (1.457–10.330) 2.939 (1.088–7.935)
Histologic steatosis 0.008 0.03
 < 5% 1 [Reference] 1 [Reference]
 ≥ 5% 3.669 (1.411–9.543) 3.005 (1.122–8.051)
Duration of antiviral treatment 0.43
 Never or <5 years 1 [Reference]
 ≥5 years 0.635 (0.205–1.963)
Albumin (g/dL) 0.874 (0.306–2.495) 0.80
Total bilirubin (mg/dL) 0.902 (0.476–1.710) 0.75
ALP (IU/L) 1.000 (0.993–1.006) 0.91
AST (IU/L) 0.994 (0.986–1.002) 0.17
ALT (IU/L) 0.990 (0.981–0.999) 0.03
GGT (IU/L) 1.000 (0.997–1.004) 0.83
Fasting glucose (mg/dL) 1.012 (0.999–1.024) 0.07
Total cholesterol (mg/dL) 0.993 (0.978–1.008) 0.33
HDL cholesterol (mg/dL) 1.010 (0.979–1.042) 0.54
LDL cholesterol (mg/dL) 0.988 (0.970–1.008) 0.23
Triglyceride (mg/dL) 0.995 (0.982–1.008) 0.45
HBeAg (positive) 0.850 (0.313–2.305) 0.75
HBV DNA 0.75
 <6 log10 copies/mL 1 [Reference]
 ≥6 log10 copies/mL 0.841 (0.297–2.383)

Data in parentheses are 95% CIs.

HCC, hepatocellular carcinoma; CI, confidence interval; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

*Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

Table 4.
Baseline clinicopathological characteristics after inverse probability weighting
Table 4.
Characteristics Overall (N=321) Steatosis
 P-value
< 5% (n=251) ≥ 5% (n=70)
Age (median [IQR]) (years) 41 (34–49) 42 (33–49) 40 (34–50) 0.72
Male 186 (57.8) 151 (60.7) 35 (47.9) 0.28
BMI (kg/m2) 0.74
 <23 (Normal) 138 (42.8) 104 (41.9) 33 (45.8)
 ≥23 to <25 (Overweight) 75 (23.2) 62 (24.8) 13 (17.6)
 ≥25 (Obese) 110 (34.1) 83 (33.4) 27 (36.6)
Diabetes mellitus 18 (5.5) 15 (5.8) 3 (4.4) 0.58
Hypertension 29 (8.9) 23 (9.2) 6 (8.2) 0.83
Number of metabolic risk factors* 0.43
 <3 266 (82.7) 209 (84.0) 57 (78.1)
 ≥3 56 (17.3) 40 (16.0) 16 (21.9)
Liver cirrhosis 81 (25.0) 51 (20.4) 30 (41.1) 0.08
Duration of antiviral treatment 0.42
 Never or <5 years 158 (49.0) 117 (46.9) 41 (56.2)
 ≥5 years 164 (51.0) 132 (53.1) 32 (43.8)
Laboratory data (median [IQR])
 Albumin (g/dL) 4.0 (3.7–4.3) 4 (3.7–4.4) 3.9 (3.4–4.3) 0.19
 Total bilirubin (mg/dL) 0.7 (0.5–1.0) 0.6 (0.5–1.0) 0.8 (0.5–1.0) 0.53
 ALP (IU/L) 192 (157–250) 189 (156–243) 224 (169–250) 0.31
 AST (IU/L) 73 (47–136) 79 (49–143) 56 (47–106) 0.30
 ALT (IU/L) 78 (39–159) 87 (43–169) 65 (25–114) 0.68
 GGT (IU/L) 65 (33–126) 61 (33–113) 70 (33–178) 0.33
 Fasting glucose (mg/dL) 99 (90–112) 98 (90–111) 101 (92–124) 0.49
 Total cholesterol (mg/dL) 159 (136–180) 163 (140–180) 153 (136–181) 0.44
 HDL cholesterol (mg/dL) 49 (39.4–59.4) 47.0 (39.4–58.5) 54.0 (39.5–59.4) 0.35
 LDL cholesterol (mg/dL) 90 (74–110) 92 (77–110) 79 (69–105) 0.29
 Triglyceride (mg/dL) 87 (66–113) 84 (65–114) 94 (79–107) 0.25
 HBeAg (positive) 222 (68.9) 167 (67.2) 54 (74.7) 0.37
 HBV DNA 0.21
  <6 log10 copies/mL 155 (48.2) 112 (45.0) 43 (59.2)
  ≥6 log10 copies/mL 167 (51.8) 137 (55.0) 30 (40.8)

Data are given as number (%) of patients, unless otherwise noted.

IQR, interquartile range; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gammaglutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

*Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

Table 5.
Univariate and multivariate Cox analysis of factors associated with HCC development after inverse probability weighting
Table 5.
Characteristics HCC development
Univariate analysis
 Multivariate analysis
Hazard ratio (95% CI) P-value Adjusted hazard ratio (95% CI) P-value
Age (years) 1.077 (1.025–1.132) 0.003 1.063 (1.010–1.120) 0.02
Male 1.349 (0.382–4.760) 0.64
BMI (kg/m2) 0.93
 <23 (Normal) 1 [Reference]
 ≥23 to <25 (Overweight) 1.300 (0.35–4.828) 0.70
 ≥25 (Obese) 1.123 (0.269–4.692) 0.87
Diabetes mellitus 0.004 0.03
 No 1 [Reference] 1 [Reference]
 Yes 5.331 (1.686–16.853) 3.562 (1.117–11.359)
Hypertension 0.14
 No 1 [Reference]
 Yes 2.951 (0.700–12.444)
Number of metabolic risk factors* 0.98
 <3 1 [Reference]
 ≥3 1.022 (0.192–5.433)
Liver cirrhosis 0.01 0.07
 No 1 [Reference] 1 [Reference]
 Yes 4.371 (1.373–13.918) 3.554 (0.911–13.874)
Histologic steatosis 0.10 0.47
 < 5% 1 [Reference] 1 [Reference]
 ≥ 5% 2.620 (0.828–8.297) 1.709 (0.404–7.228)
Duration of antiviral treatment 0.77
 Never or <5 years 1 [Reference]
 ≥5 years 0.838 (0.252–2.784)
Albumin (g/dL) 0.689 (0.303–1.565) 0.37
Total bilirubin (mg/dL) 0.953 (0.692–1.311) 0.77
ALP (IU/L) 0.999 (0.992–1.005) 0.72
AST (IU/L) 0.995 (0.988–1.003) 0.25
ALT (IU/L) 0.994 (0.985–1.004) 0.23
GGT (IU/L) 1.002 (0.999–1.006) 0.22
Fasting glucose (mg/dL) 1.014 (1.000–1.028) 0.05
Total cholesterol (mg/dL) 1.001 (0.989–1.013) 0.92
HDL cholesterol (mg/dL) 1.007 (0.959–1.057) 0.79
LDL cholesterol (mg/dL) 0.997 (0.97–1.025) 0.83
Triglyceride (mg/dL) 1.002 (0.993–1.01) 0.69
HBeAg (positive) 0.806 (0.232–2.804) 0.74
HBV DNA 0.77
 <6 log10 copies/mL 1 [Reference]
 ≥6 log10 copies/mL 0.814 (0.21–3.164)

Data in parentheses are 95% CIs.

HCC, hepatocellular carcinoma; CI, confidence interval; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

*Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

ALT

alanine aminotransferase

BMI

body mass index

CHB

chronic hepatitis B

CI

confidence interval

HBeAg

hepatitis B e antigen

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

HR

hazards ratio

IPW

inverse probability weighting

IQR

interquartile range

NAFLD

nonalcoholic fatty liver disease

NASH

nonalcoholic steatohepatitis
  • 1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546-1555.
  • 2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-1956.
  • 3. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004;24 Suppl 1:17-21.
  • 4. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006;26:130-141.
  • 5. Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014;384:2053-2063.
  • 6. Sanyal AJ; American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-1725.
  • 7. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002;9:37-51.
  • 8. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-1978.
  • 9. Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol 2017;32:667-676.
  • 10. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111-121.
  • 11. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328-357.
  • 12. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-348.
  • 13. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163.
  • 14. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-1645.
  • 15. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009;15:391-423.
  • 16. Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 2015;16:465-522.
  • 17. Bruix J, Sherman M; Practice Guidelines Committee; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236.
  • 18. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
  • 19. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344:495-500.
  • 20. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
  • 21. Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology 2017;153:1006-1017 e5.
  • 22. Wang MM, Wang GS, Shen F, Chen GY, Pan Q, Fan JG. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci 2014;59:2571-2579.
  • 23. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
  • 24. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56:1751-1759.
  • 25. Bedossa P; FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014;60:565-575.
  • 26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Clin Mol Hepatol. 2019;25(1):52-64.   Published online October 23, 2018
DOI: https://doi.org/10.3350/cmh.2018.0040
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
Format:
Include:
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Clin Mol Hepatol. 2019;25(1):52-64.   Published online October 23, 2018
DOI: https://doi.org/10.3350/cmh.2018.0040
Close

Figure

  • 0
  • 1
  • 2

Related articles

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Image Image Image
Figure 1. Flowchart of patient identification for the study. A total of 321 patients with chronic HBV infection were included in the analysis. HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HBV, hepatitis B virus.
Figure 2. Incidence of HCC. (A) In the entire cohort. (B) Among patients with or without fatty liver. (C) Among patients with or without fatty liver in the subgroup without cirrhosis (Ishak F0–4). (D) Among patients with or without fatty liver in the subgroup with cirrhosis (Ishak F5/6). HCC, hepatocellular carcinoma.
Figure 3. Incidence of HCC after IPW. (A) In the entire cohort. (B) Among patients with or without fatty liver. (C) Among patients with or without fatty liver in the subgroup without cirrhosis (Ishak F0–4). (D) Among patients with or without fatty liver in the subgroup with cirrhosis (Ishak F5/6). HCC, hepatocellular carcinoma; IPW, inverse probability weighting.

Figure 1.

Figure 2.

Figure 3.

Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B
Characteristics Overall (N=321) Steatosis
 P-value
< 5% (n=251) ≥ 5% (n=70)
Age (median [IQR]) (years) 41 (33–49) 41 (32–48) 45 (36–51) 0.005
Male 196 (61.1) 146 (58.2) 50 (71.4) 0.05
BMI (kg/m2) <0.001
 <23 (Normal) 134 (41.7) 118 (47.0) 16 (22.9)
 ≥23 to <25 (Overweight) 81 (25.2) 66 (26.3) 15 (21.4)
 ≥25 (Obese) 106 (33.0) 67 (26.7) 39 (55.7)
Diabetes mellitus 21 (6.5) 13 (5.2) 8 (11.4) 0.06
Hypertension 25 (7.8) 14 (5.6) 11 (15.7) 0.005
Number of metabolic risk factors* <0.001
 <3 269 (83.8) 223 (88.8) 46 (65.7)
 ≥3 52 (16.2) 28 (11.2) 24 (34.3)
Liver cirrhosis 64 (19.9) 45 (17.9) 19 (27.1) 0.09
Duration of antiviral treatment 0.88
 Never or <5 years 154 (48.0) 121 (48.2) 33 (47.1)
 ≥5 years 167 (52.0) 130 (51.8) 37 (52.9)
Laboratory data (median [IQR])
 Albumin (g/dL) 4.0 (3.7–4.3) 4.0 (3.7–4.3) 4.2 (3.8–4.4) 0.17
 Total bilirubin (mg/dL) 0.6 (0.5–0.9) 0.7 (0.5–0.9) 0.6 (0.5–0.9) 0.53
 ALP (IU/L) 185 (154–241) 191 (156–245) 176 (150–227) 0.17
 AST (IU/L) 76 (47–140) 85 (51–153) 53 (36–86) <0.001
 ALT (IU/L) 87 (44–160) 94 (45–171) 71 (32–114) 0.02
 GGT (IU/L) 61 (32–112) 66 (33–115) 52 (30–104) 0.51
 Fasting glucose (mg/dL) 98 (90–109) 98 (90–108) 103 (92–117) 0.09
 Total cholesterol (mg/dL) 164 (140–183) 159 (137–179) 176 (155–203) <0.001
 HDL cholesterol (mg/dL) 47.3 (38.8–58.4) 48.3 (39.4–59.4) 44.4 (35.4–54.4) 0.21
 LDL cholesterol (mg/dL) 92 (76–112) 90 (75–108) 105 (87–129) <0.001
 Triglyceride (mg/dL) 84 (65–115) 80 (63–109) 103 (81–137) <0.001
 HBeAg (positive) 218 (67.9) 176 (70.1) 42 (60.0) 0.11
 HBV DNA 0.26
  <6 log10 copies/mL 146 (45.5) 110 (43.8) 36 (51.4)
  ≥6 log10 copies/mL 175 (54.5) 141 (56.2) 34 (48.6)
HCC development Overall Steatosis < 5% Steatosis ≥ 5%
Overall
 1-year Rate (%) 0 0 0
Sample size 310 243 67
 3-year Rate (%) 1.8 1.9 1.6
Sample size 238 184 54
 5-year Rate (%) 3.2 1.9 8.2
Sample size 164 136 28
Ishak F0–4
 1-year Rate (%) 0 0 0
Sample size 248 198 50
 3-year Rate (%) 0.9 1.1 0
Sample size 191 151 40
 5-year Rate (%) 2.1 1.1 6.0
Sample size 141 120 21
Ishak F5/6
 1-year Rate (%) 0 0 0
Sample size 62 45 17
 3-year Rate (%) 5.6 5.3 5.9
Sample size 47 33 14
 5-year Rate (%) 8.0 5.3 13.7
Sample size 23 16 7
Characteristics HCC development
Univariate analysis
 Multivariate analysis
Hazard ratio (95% CI) P-value Adjusted hazard ratio (95% CI) P-value
Age (years) 1.105 (1.057–1.155) <0.001 1.109 (1.057–1.164) <0.001
Male 1.403 (0.494–3.986) 0.53
BMI (kg/m2) 0.52
 <23 (Normal) 1 [Reference]
 ≥23 to <25 (Overweight) 1.851 (0.535–6.403) 0.33
 ≥25 (Obese) 1.826 (0.579–5.761) 0.30
Diabetes mellitus 0.002
 No 1 [Reference]
 Yes 6.019 (1.893–19.139)
Hypertension 0.008
 No 1 [Reference]
 Yes 4.138 (1.452–11.791)
Number of metabolic risk factors* 0.95
 <3 1 [Reference]
 ≥3 1.045 (0.299–3.651)
Liver cirrhosis 0.007 0.03
 No 1 [Reference] 1 [Reference]
 Yes 3.880 (1.457–10.330) 2.939 (1.088–7.935)
Histologic steatosis 0.008 0.03
 < 5% 1 [Reference] 1 [Reference]
 ≥ 5% 3.669 (1.411–9.543) 3.005 (1.122–8.051)
Duration of antiviral treatment 0.43
 Never or <5 years 1 [Reference]
 ≥5 years 0.635 (0.205–1.963)
Albumin (g/dL) 0.874 (0.306–2.495) 0.80
Total bilirubin (mg/dL) 0.902 (0.476–1.710) 0.75
ALP (IU/L) 1.000 (0.993–1.006) 0.91
AST (IU/L) 0.994 (0.986–1.002) 0.17
ALT (IU/L) 0.990 (0.981–0.999) 0.03
GGT (IU/L) 1.000 (0.997–1.004) 0.83
Fasting glucose (mg/dL) 1.012 (0.999–1.024) 0.07
Total cholesterol (mg/dL) 0.993 (0.978–1.008) 0.33
HDL cholesterol (mg/dL) 1.010 (0.979–1.042) 0.54
LDL cholesterol (mg/dL) 0.988 (0.970–1.008) 0.23
Triglyceride (mg/dL) 0.995 (0.982–1.008) 0.45
HBeAg (positive) 0.850 (0.313–2.305) 0.75
HBV DNA 0.75
 <6 log10 copies/mL 1 [Reference]
 ≥6 log10 copies/mL 0.841 (0.297–2.383)
Characteristics Overall (N=321) Steatosis
 P-value
< 5% (n=251) ≥ 5% (n=70)
Age (median [IQR]) (years) 41 (34–49) 42 (33–49) 40 (34–50) 0.72
Male 186 (57.8) 151 (60.7) 35 (47.9) 0.28
BMI (kg/m2) 0.74
 <23 (Normal) 138 (42.8) 104 (41.9) 33 (45.8)
 ≥23 to <25 (Overweight) 75 (23.2) 62 (24.8) 13 (17.6)
 ≥25 (Obese) 110 (34.1) 83 (33.4) 27 (36.6)
Diabetes mellitus 18 (5.5) 15 (5.8) 3 (4.4) 0.58
Hypertension 29 (8.9) 23 (9.2) 6 (8.2) 0.83
Number of metabolic risk factors* 0.43
 <3 266 (82.7) 209 (84.0) 57 (78.1)
 ≥3 56 (17.3) 40 (16.0) 16 (21.9)
Liver cirrhosis 81 (25.0) 51 (20.4) 30 (41.1) 0.08
Duration of antiviral treatment 0.42
 Never or <5 years 158 (49.0) 117 (46.9) 41 (56.2)
 ≥5 years 164 (51.0) 132 (53.1) 32 (43.8)
Laboratory data (median [IQR])
 Albumin (g/dL) 4.0 (3.7–4.3) 4 (3.7–4.4) 3.9 (3.4–4.3) 0.19
 Total bilirubin (mg/dL) 0.7 (0.5–1.0) 0.6 (0.5–1.0) 0.8 (0.5–1.0) 0.53
 ALP (IU/L) 192 (157–250) 189 (156–243) 224 (169–250) 0.31
 AST (IU/L) 73 (47–136) 79 (49–143) 56 (47–106) 0.30
 ALT (IU/L) 78 (39–159) 87 (43–169) 65 (25–114) 0.68
 GGT (IU/L) 65 (33–126) 61 (33–113) 70 (33–178) 0.33
 Fasting glucose (mg/dL) 99 (90–112) 98 (90–111) 101 (92–124) 0.49
 Total cholesterol (mg/dL) 159 (136–180) 163 (140–180) 153 (136–181) 0.44
 HDL cholesterol (mg/dL) 49 (39.4–59.4) 47.0 (39.4–58.5) 54.0 (39.5–59.4) 0.35
 LDL cholesterol (mg/dL) 90 (74–110) 92 (77–110) 79 (69–105) 0.29
 Triglyceride (mg/dL) 87 (66–113) 84 (65–114) 94 (79–107) 0.25
 HBeAg (positive) 222 (68.9) 167 (67.2) 54 (74.7) 0.37
 HBV DNA 0.21
  <6 log10 copies/mL 155 (48.2) 112 (45.0) 43 (59.2)
  ≥6 log10 copies/mL 167 (51.8) 137 (55.0) 30 (40.8)
Characteristics HCC development
Univariate analysis
 Multivariate analysis
Hazard ratio (95% CI) P-value Adjusted hazard ratio (95% CI) P-value
Age (years) 1.077 (1.025–1.132) 0.003 1.063 (1.010–1.120) 0.02
Male 1.349 (0.382–4.760) 0.64
BMI (kg/m2) 0.93
 <23 (Normal) 1 [Reference]
 ≥23 to <25 (Overweight) 1.300 (0.35–4.828) 0.70
 ≥25 (Obese) 1.123 (0.269–4.692) 0.87
Diabetes mellitus 0.004 0.03
 No 1 [Reference] 1 [Reference]
 Yes 5.331 (1.686–16.853) 3.562 (1.117–11.359)
Hypertension 0.14
 No 1 [Reference]
 Yes 2.951 (0.700–12.444)
Number of metabolic risk factors* 0.98
 <3 1 [Reference]
 ≥3 1.022 (0.192–5.433)
Liver cirrhosis 0.01 0.07
 No 1 [Reference] 1 [Reference]
 Yes 4.371 (1.373–13.918) 3.554 (0.911–13.874)
Histologic steatosis 0.10 0.47
 < 5% 1 [Reference] 1 [Reference]
 ≥ 5% 2.620 (0.828–8.297) 1.709 (0.404–7.228)
Duration of antiviral treatment 0.77
 Never or <5 years 1 [Reference]
 ≥5 years 0.838 (0.252–2.784)
Albumin (g/dL) 0.689 (0.303–1.565) 0.37
Total bilirubin (mg/dL) 0.953 (0.692–1.311) 0.77
ALP (IU/L) 0.999 (0.992–1.005) 0.72
AST (IU/L) 0.995 (0.988–1.003) 0.25
ALT (IU/L) 0.994 (0.985–1.004) 0.23
GGT (IU/L) 1.002 (0.999–1.006) 0.22
Fasting glucose (mg/dL) 1.014 (1.000–1.028) 0.05
Total cholesterol (mg/dL) 1.001 (0.989–1.013) 0.92
HDL cholesterol (mg/dL) 1.007 (0.959–1.057) 0.79
LDL cholesterol (mg/dL) 0.997 (0.97–1.025) 0.83
Triglyceride (mg/dL) 1.002 (0.993–1.01) 0.69
HBeAg (positive) 0.806 (0.232–2.804) 0.74
HBV DNA 0.77
 <6 log10 copies/mL 1 [Reference]
 ≥6 log10 copies/mL 0.814 (0.21–3.164)
Table 1. Baseline clinicopathological characteristics

Data are given as number (%) of patients, unless otherwise noted.

IQR, interquartile range; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gammaglutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

Table 2. Development of HCC

HCC, hepatocellular carcinoma.

Table 3. Univariate and multivariate Cox analysis of the factors associated with HCC development

Data in parentheses are 95% CIs.

HCC, hepatocellular carcinoma; CI, confidence interval; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

Table 4. Baseline clinicopathological characteristics after inverse probability weighting

Data are given as number (%) of patients, unless otherwise noted.

IQR, interquartile range; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gammaglutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

Table 5. Univariate and multivariate Cox analysis of factors associated with HCC development after inverse probability weighting

Data in parentheses are 95% CIs.

HCC, hepatocellular carcinoma; CI, confidence interval; BMI, body mass index; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

Metabolic risk factors included obesity, history of hypertension or diabetes mellitus, and serum levels of triglyceride, HDL cholesterol, and fasting glucose.

Table 1.

Table 2.

Table 3.

Table 4.

Table 5.

CMH : Clinical and Molecular Hepatology
Twitter

ABOUT

BROWSE ARTICLES

FOR CONTRIBUTORS

© The Korean Association for the Study of the Liver.